[Skip to content]
This section contains information on decisions made by the East Sussex Health Economy Medicines Committee relating to individual treatments and treatment pathways
3, 4 Diaminopyridine (phosphate form) (Firdapse®) for treatment of Lambert-Eaton myasthenic syndrome and Congenital Myasthenia Syndromes.
Botulinum Toxin to manage spasticity in stroke rehabilitation and Multiple Sclerosis
Treatment Strategy for the use of Biologics in Rheumatoid Arthritis
Sapropterin for the management of Phenylketonuria
Cannabinoid Spray (Sativex®) for MS related spasticity
Drug treatment pathway for Osteoporosis in Postmenopausal Women
Dabigatran etexilate for the prevention of stroke or systemic embolism in people with atrial fibrillation
Guidance on prescribing
